Rudy Lee

“Just a quick follow-up to the market dynamics. So apparently there are a lot of discussion on short duration versus long duration psychedelics following the leading deal.”

“Maybe just a quick follow-up to the patient dynamic for the STIC formulation. Can you maybe talk about the trend moving into July and August across different vision segments?”

“I have a question for the pipeline, just a quick follow-up. Given the trajectory of CodeBanvi and the feedback, I'm just curious on your thoughts on the muskronik opportunity and maybe to talk about your overall strategy building a muskronik franchise as you have multiple products maybe targeting different indications.”

“I just have a follow-up question on Ingraza. I think we touched on seasonality already. Can you provide more color on the pattern for the remaining three quarters, especially given the relatively stronger 1Q versus prior years?”

“Just a quick follow-up to your long-term guidance of AB in ovality cells. How should we think about the uptake maybe for the relatively near term, maybe in the next two, three years?”